Use of oxibendazole for control of cambendazole-resistant small strongyles in a band of ponies: a six-year study.
Oxibendazole (OBZ; 10 mg/kg of body weight) was administered to ponies at 8-week intervals to control strongylosis in a breeding band of Shetland-type ponies (n = 29 to 50) from October 1978 through September 1984. A similar use of cambendazole (CBZ; 20 mg/kg of body weight) in this band of ponies during the preceding 4-year period resulted in the survival of a CBZ-resistant population (S) of small strongyles. Effectiveness of OBZ treatments was monitored by pre- and posttreatment counts of the number of strongyle eggs per gram of feces (epg) and of the number of strongyle larvae per gram of feces (lpg). For the first 4 years of the 6-year period, epg and lpg counts were determined for 3 to 5 of the OBZ treatments; during the last 2 years, counts were determined for each treatment. For the 1st year, the mean reduction in epg was 96%. During the 2nd and 3rd years, mean reductions in epg were 80% and 81%, respectively. For the 4th and 5th years, mean reductions in epg were 69% and 43%, respectively. For the 6th year, the mean reduction in epg was 37%. Statistical analyses of the epg data, using the linear plateau method, indicated a significant increase in residual (surviving) strongyle infections after the periodic OBZ treatments, with a mean annual increase in survival of 10.3% for the 6 years. Changes in lpg were variable, but an overall loss of effectiveness of the OBZ treatments was evident. Only infective larvae of small strongyles were observed in the cultures; larvae of 2 species of large strongyles, Strongylus vulgaris and Strongylus edentatus, were conspicuously absent.(ABSTRACT TRUNCATED AT 250 WORDS)
D000818:Animals; D001562:Benzimidazoles / Q000627:therapeutic use*; D002159:Cambendazole / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006736:Horses; D008297:Male; D010270:Parasite Egg Count; D013319:Strongyle Infections, Equine / Q000188:drug therapy* / Q000469:parasitology; D013320:Strongyloidea / Q000187:drug effects; D013997:Time Factors
D001562:Benzimidazoles; C011321:oxibendazole; D002159:Cambendazole